Predicting long-term outcomes for Chinese women with breast cancer receiving chemotherapy
Machine Learning Models for Predicting Long-Term Clinical Outcomes in Chinese Female Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
This study is trying to see if advanced AI can help predict long-term outcomes for Chinese women with breast cancer who have received chemotherapy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 6000 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | Female |
| Sponsor | The Second Affiliated Hospital of Harbin Medical University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Harbin, Longjiang Hei) |
| Trial ID | NCT06856616 on ClinicalTrials.gov |
What this trial studies
This observational study aims to utilize advanced artificial intelligence techniques to predict long-term clinical outcomes in Chinese women with invasive breast cancer who have undergone neoadjuvant chemotherapy. By integrating AI with imaging, pathology, and genomic data, the study seeks to develop non-invasive tools that can accurately assess prognosis and the likelihood of achieving a pathological complete response. The research will analyze data from patients treated between 2008 and 2019, focusing on clinical, pathological, and prognostic information to enhance preoperative diagnosis and postoperative survival assessments.
Who should consider this trial
Good fit: Ideal candidates are women with Stage II-III invasive breast cancer who have received neoadjuvant chemotherapy and have the necessary imaging and pathological data.
Not a fit: Patients who have received prior treatments before neoadjuvant chemotherapy or those with metastatic disease may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a reliable non-invasive method for predicting outcomes in breast cancer patients, potentially leading to personalized treatment strategies.
How similar studies have performed: Other studies have shown promise in using AI for cancer prognosis, indicating that this approach may lead to significant advancements in patient care.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Women with invasive breast cancer who received neoadjuvant chemotherapy (NAC) treatment in various hospitals from 2008 to 2019 (follow-up endpoint December 31, 2024) 2. Women with primary breast cancer (Stage II-III) confirmed by pre-NAC needle biopsy, along with recorded clinical, pathological, and prognostic information 3. With MR images before the first cycle of NAC and before surgery 4. With pathological HE staining images, including biopsy pathology and postoperative major pathology Exclusion Criteria: 1. Any form of treatment was received before NAC, including endocrine therapy, radiotherapy, and chemotherapy 2. Disease metastasis occurred during NAC 3. Breast cancer patients with secondary malignancies from other cancers 4. Patients did not complete surgery and were lost to follow-up
Where this trial is running
Harbin, Longjiang Hei
- Ming Niu — Harbin, Longjiang Hei, China (Recruiting)
Study contacts
- Study coordinator: Ming Niu, Ph.D.
- Email: niuming2024@126.com
- Phone: 13895721945
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.